New insights into the genetic basis of vitiligo and its treatment options

Abstract

A 34-year-old schoolteacher noticed small white patches spreading across her hands three weeks before her wedding—a scenario repeated thousands of times each year in Scandinavian dermatology clinics, yet one for which clinicians still lack reliable predictive tools. This research investigated the genetic underpinnings and treatment responses in a Danish cohort of 243 vitiligo patients enrolled between March 2020 and December 2021 at two academic medical centers. Whole-exome sequencing was performed to identify risk variants across established susceptibility loci, and treatment outcomes were compared across five therapeutic modalities. The HLA-A locus showed the highest variant frequency in generalized vitiligo at 52.6%, followed by TYR at 41.2%. Combination therapy involving narrowband ultraviolet B phototherapy with topical tacrolimus produced the highest mean repigmentation rates at 68.4%, surpassing monotherapy approaches. Autoimmune comorbidities were notably prevalent, with thyroid disease affecting 31.4% of participants compared to 9.2% in age-matched controls (OR 4.53, 95% CI: 2.87-7.14). Genetic profiling identified a novel FOXD3 variant enriched in segmental vitiligo at 35.1% versus 18.9% in generalized forms (p = 0.008). These findings point toward genotype-informed treatment selection as a promising direction for personalized vitiligo management.